-
-
-
-
15865-10A thiazolamine that inhibits LTB4 synthesis in human neutrophils (IC<sub>50</sub> = ~0.5 µM) and conversion of LTA4 to LTB4 by purified LTA4 hydrolase (Ki = 2.
-
15865-100A thiazolamine that inhibits LTB4 synthesis in human neutrophils (IC<sub>50</sub> = ~0.5 µM) and conversion of LTA4 to LTB4 by purified LTA4 hydrolase (Ki = 2.
-
15865-5A thiazolamine that inhibits LTB4 synthesis in human neutrophils (IC<sub>50</sub> = ~0.5 µM) and conversion of LTA4 to LTB4 by purified LTA4 hydrolase (Ki = 2.
-
15865-50A thiazolamine that inhibits LTB4 synthesis in human neutrophils (IC<sub>50</sub> = ~0.5 µM) and conversion of LTA4 to LTB4 by purified LTA4 hydrolase (Ki = 2.
-
17132-1An orally bioavailable antagonist of the androgen receptor (IC<sub>50</sub> = 16 nM) at 30 mg/kg/d, suppresses tumor growth in a mouse model of castration-resistant prostate cancer.
-
17132-10An orally bioavailable antagonist of the androgen receptor (IC<sub>50</sub> = 16 nM) at 30 mg/kg/d, suppresses tumor growth in a mouse model of castration-resistant prostate cancer.
-
17132-5An orally bioavailable antagonist of the androgen receptor (IC<sub>50</sub> = 16 nM) at 30 mg/kg/d, suppresses tumor growth in a mouse model of castration-resistant prostate cancer.
-
16065-1A fluorinated analog of AEA that serves as a substrate of FAAH (Km = 29 µM) used to perform n-FABS against FAAH to identify novel inhibitors.
-
16065-10A fluorinated analog of AEA that serves as a substrate of FAAH (Km = 29 µM) used to perform n-FABS against FAAH to identify novel inhibitors.